Induced sputum in interstitial lung diseases

Current Opinion in Pulmonary Medicine

Volumn 12, Issue 5, 2006, Pages 318-322

  Fireman, Elizabeth ^a,b   Lerman, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Induced sputum; Occupational exposures; Sarcoidosis

Indexed keywords

BRONCHIOLITIS OBLITERANS; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HUMAN; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LEUKOCYTE DIFFERENTIAL COUNT; LOGISTIC REGRESSION ANALYSIS; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; NEUTROPHIL; OCCUPATIONAL LUNG DISEASE; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; TECHNOLOGY; TISSUE SECTION;

BRONCHOALVEOLAR LAVAGE; HUMANS; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE COUNT; SPUTUM; T-LYMPHOCYTE SUBSETS;

EID: 33748163585     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000239547.62949.82     Document Type: Review

References (47)

1. Fireman E. Induced sputum: opening a new window to the lung. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:263-271.
2. George SC, Hogman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol 2004; 96:831-839.
3. Montuschi P, Barnes PJ. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci 2002; 23:232-237.
4. Keatings V, Leigh R, Peterson C, et al. Analysis of fluid phase mediators. Eur Respir J 2002; 20:24S-39S.
5. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47:25-29.
6. Fireman E, Greif J, Bologovov E, et al. Evaluation of occupational lung diseases by induced sputum compared to bronchoalveolar lavage. Chest 1999; 11:1720-1728.
7. Lerman Y, Segal B, Rochvarger M, et al. Induced-sputum particle size distribution and pulmonary function in foundry workers. Arch Environ Health 2003; 58:565-571.
8. Lerman Y, Schwarz Y, Kaufman G, et al. Case series: use of induced sputum in the evaluation of occupational lung diseases. Arch Environ Health 2003; 58:284-289.
9. Fireman E, Goshen M, Ganor E, et al. Induced sputum as an additional tool in the identification of metal-induced sarcoid-like reaction. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:152-156.
10. Fireman E, Topilsky I, Greif J, et al. Evaluation of interstitial lung diseases by induced sputum compared to bronchoalveolar lavage. Respir Med 1999; 93:827-834.
11. D'Ippolito R, Foresi A, Chetta A, et al. Induced sputum in patients with newly diagnosed sarcoidosis. Chest 1999; 115:1611-1615.
12. Moodley YP, Dorasamy T, Venketasamy S, et al. Correlation of CD4/CD8 ratio and TNF α levels in induced sputum with bronchoalveolar lavage fluid in pulmonary sarcoidosis. Thorax 2000; 55:696-699.
13. Tsiligianni J, Tzanakis N, Kyriakou D, et al. Comparison of sputum induction with bronchoalveolar lavage cell differential counts in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 193:205-210.
14. Mroz RM, Chyczewska E, Korniluk M, et al. Comparison of cellular composition of induced sputum, bronchial washings and bronchoalveolar lavage fluid in sarcoidosis, hypersensitivity pneumonitis and COPD. Pneumonol Alergol Pol 2002; 70:468-477.
15. Neudorfer M, Leibovitch J, Onn A, et al. The use of induced sputum in the assessment of patients with uveitis. Ophthalmology 2002; 109:858-861.
16. Fireman Z, Osipov A, Kivity S, et al. The use of induced sputum in the assessment of pulmonary involvement in Crohn's disease. Am J Gastroenterol 2000; 95:730-734.
17. Klech H, Pohl W. Technical recommendations and guidelines for bronchoalveolar lavage (BAL) Report of the ERS Task Group. Eur Respir J 1989; 2:561-585.
18. Drent M, Mulder PGH, Wagenaar SS, et al. Differences in BAL fluid variables in interstitial lung diseases evaluated by discriminant analysis. Eur Respir J 1993; 6:803-810.
19. Fahy JV, Wong H, Liu J, Boushey HA. Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. Am J Respir Crit Care Med 1995; 152:53-58.
20. Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies and bronchoalveolar lavage. Am J Crit Care Med 1995; 152:1926-1931.
21. Welker L, Jörres RA, Costabel U, Magnussen H. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004; 24:1000-1006.
22. D'Ippolito R, Chetta A, Foresi A, et al. Induced sputum and bronchoalveolar lavage from patients with hypersensitivity pneumonitis. Respir Med 2004; 98:977-983.
23. Antoniou KM, Alexandrakis M, Tzanakis N, et al. Induced sputum versus bronchoalveolar lavage fluid in the evaluation of patients with idiopathic pulmonary fibrosis. Respiration 2005; 72:32-38.
24. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Granulomatous Disorders. Am J Respir Crit Care Med 1999; 160:736-755.
25. Fireman E, Boikaner T, Priel I. Combined CD4/CD8 ratio in induced sputum and pulmonary function testing for non-invasive identification of sarcoidosis. J Lab Clin Med 2006 (in press).
26. Ohtsuka M, Yoshizawa Y, Naitou T, et al. The motility of lung lymphocytes in hypersensitivity pneumonitis and sarcoidosis. Am J Respir Crit Care Med 1994; 149:455-459.
27. Bjermer L, Thunell M, Rosenhall L, Stjernberg N. Endobronchial biopsy positive sarcoidosis: relation to bronchoalveolar lavage and course of disease. Respir Med 1991; 85:229-234.
28. Brandtzaeg P, Farstad I, Guttorn H. Regional specialization in the mucosa immune system: primed cells do not always home along the same track. Immunol Today 1999; 6:267-277.
29. Bingaman AW, Patke DS, Mane VR, et al. Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in lymphoid and lung tissue. Eur J Immunol 2005; 35:3173-3186.
30. Beeh KM, Beier J, Kornmann O, Buhl R. Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:138-143.
31. Birring SS, Parker D, McKenna S, et al. Sputum eosinophilia in idiopathic pulmonary fibrosis. Inflamm Res 2005; 54:51-56.
32. Fireman E, Lerman Y. Induced sputum in occupational lung diseases. Breath 2005; 2:50-59. The review is a summary of the update data in the field, explaining the use of quantitative and qualitative analysis of inhaled particles in hazardous dust exposure, and introducing induced sputum methodology in the field of occupational lung diseases.
33. Teschler H, Thompson AB, Dollenkamp R, et al. Relevance of asbestos bodies in sputum. Eur Respir J 1996; 9:680-686.
34. Capellaro E, Chiesa A, Villari S, et al. Asbestos bodies in bronchoalveolar lavage fluid and sputum. Med Lav 1997; 88:99-107.
35. Rosenberg G, Harrison R. Biological monitoring. In: La Dou J, editor. Occupational and environmental medicine, 2nd ed. New York: Appleton & Lange; 1997. pp. 637-646.
36. Cohen C, Fireman E, Ganor E, et al. Accelerated silicosis with mixed-dust pneumoconiosis in a hard-metal grinder. J Occup Environ Med 1999; 41:480-485.
37. Fireman E, Goshen M, Ganor E, et al. Induced sputum as an additional tool in the identification of metal-induced sarcoid-like reaction. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:152-156.
38. Fireman EM, Lerman Y, Ganor E, et al. Induced sputum assessment in New York City firefighters exposed to World Trade Center dust. Environ Health Perspect 2004; 112:1564-1569.
39. Benfield JR, Wain JC. The history of lung transplantation. Chest Surg Clin North Am 2000; 10:189-199.
40. Boehler A, Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulmon Med 2000; 6:133-139.
41. Beeh KM, Kornmann O, Lill J, Buhl R. Induced sputum cell profiles in lung transplant recipients with or without chronic rejection: correlation with lung function. Thorax 2001; 56:557-560.
42. Allen DJ, Fildes JE, Yonan N, Leonard CT. Changes in induced sputum in the presence of bronchiolitis obliterans syndrome and correlation with spirometry in single and bilateral lung transplant recipients. J Heart Lung Transplant 2005; 24:88-91.
43. Paran D, Fireman E, Elkayam O. Pulmonary disease in systemic lupus erythematosus and the antiphospholipid syndrome. Autoimmun Rev 2004; 3:70-75.
44. Antoniou KM, Tzortzaki EG, Alexandrakis MG, et al. Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:204-209. The study aims to evaluate the role of T helper 1 cytokines by monitoring changes in induced sputum samples, before and after treatment with interferon-γ1b in patients with IPF.
45. Fireman E, Kraiem Z, Sade O, et al. Induced sputum-retrieved matrix metalloproteinase 9 and tissue metalloproteinase inhibitor 1 in granulomatous diseases. Clin Exp Immunol 2002; 130:331-337.
46. Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003; 97:634-639.
47. Unexpected smoking-linked high MMP-9 in induced sputum of hazardous dust-exposed workers. Mediators Inflamm 2006 (in press).